CVS Group has reported higher revenue and adjusted earnings, a larger Australian footprint and ongoing share repurchases, alongside the planned retirement of its chief executive.
CVS Group (LSE:CVSG), the FTSE 250 veterinary services provider, has spent the weeks since its 24 September full-year results buying back shares while setting out an outlook for growth after a period shaped by the Competition and Markets Authority (CMA) investigation into the veterinary market. For the year to 30 June 2026, revenue rose 5.9% to £712.8m and like-for-like sales grew 2.1%, an improvement on the 0.2% recorded in the previous year.
Earnings, margins and cash
Adjusted EBITDA increased 5.1% to £141.5m, giving a margin of 19.9%, within the company's 19%–23% guidance range. Adjusted earnings per share rose 6.9% to 85.6p and adjusted profit before tax climbed 7.6% to £84.9m. On a statutory basis the picture was weaker: operating profit fell 4.4% to £47.6m, profit before tax slipped to £32.0m, and profit for the year was £17.8m compared with £53.0m, a figure that had been flattered in 2025 by a £33.9m gain on discontinued operations. One-off costs rose to £10.6m, relating to the move to the Main Market and the CMA process.
Free cash flow was £69.2m, against £72.2m a year earlier, and operating cash conversion fell to 70.6%. Net bank borrowings increased to £199.6m from £131.4m, taking leverage to 1.63 times EBITDA, still below the 2.0 times ceiling the company says it maintains. In May the group refinanced its facilities into a £350m package running to May 2030.
The board proposed a final dividend of 9.0p per share, up from 8.5p. The shares go ex-dividend on 7 November, with payment on 4 December following the annual meeting on 25 November.
Buybacks and acquisitions
Capital returns have been a significant theme. After completing a £20m buyback in January, CVS (LSE:CVSG) launched a £50m programme on 26 May that it expects to conclude around November. The latest weekly filing, released on 12 October, showed 234,531 shares bought between 5 and 9 October at prices from 1,137p to 1,190p, averaging 1,162.42p. In total, 3,024,593 shares have been repurchased under the programme at a weighted average of 1,247.4p, and the share count after cancellation stood at 67,138,506.
Australia has become a bigger part of the business. During the year CVS bought six Australian practices covering 14 sites for an initial £43.3m, and Australian revenue rose to £79.1m, around 11% of the group, from 57 sites. Since the year end it has completed two further Australian deals for £4.9m, exchanged contracts on two more for a combined £4.0m and agreed to buy a two-site UK practice for an initial £15.0m.
Regulation and leadership
The CMA issued its final decision on 24 March 2026, and final remedies orders were published on 22 September. CVS said the cost of implementing the remedies was £5.1m.
Chief executive Richard Fairman, who described another year of solid growth across the group's three divisions, used the results to announce his intention to retire. He will remain in post until a successor is in place.
Looking ahead, the company reported a solid start to the new financial year with positive like-for-like growth and said it expects 2027 to be in line with market expectations. It cited company-compiled consensus of adjusted EBITDA averaging £150.4m and adjusted earnings per share averaging 94.9p, and reiterated its medium-term ambition of returning to 4%–8% like-for-like organic growth.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...